IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re the Application of:) Group Art Unit: 1656
David Bar-Or) Confirmation No.: 3907
Serial No.: 10/723,247	Examiner: Samuel W. Liu
Filed: November 25, 2003	
Atty. File No.: 6134-82	SUPPLEMENTAL INFORMATION DISCLOSURE
Entitled: "Treatment of Diseases and Conditions	STATEMENT
Mediated by Increased Phosphorylation")
Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450	Electronically Submitted
Dear Sir:	
The references cited on attached Form PTC	0-1449 are being called to the attention
of the Examiner.	
Copies of the cited non-patent and/or foreign	n references are enclosed herewith.
Copies of the cited U.S. patents and/or patent Copies of the cited U.S. patents/patent appl	at applications are enclosed herewith.
Copies of the cited U.S. patents/patent appl	ication publications are not enclosed in
accordance with 37 C.F.R. § 1.98(a).	
Copies of the cited references are not en	closed, in accordance with 37 C.F.R.
§ 1.98(d), because the references were cited by	
Trademark Office in prior application Serial No	
which is relied upon for an earlier filing date under	35 U.S.C. § 120.
To the best of applicants' belief, the pertine	
are believed to be summarized in the attached Engli	sh abstracts and in the figures, although
applicants do not necessarily vouch for the accuracy	of the translation.
Examiner's attention is drawn to the following	ng related applications:
Serial No filed	(Attorney Ref. No)
Serial No filed	(Attorney Ref. No)
Other:	
Submission of the above information is not i	ntended as an admission that any item
s citable under the statutes or rules to support a reje	ction, that any item disclosed
represents analogous art, or that those skilled in the	art would refer to or recognize the
pertinence of any reference without the benefit of hi	ndsight, nor should an inference be

drawn as to the pertinence of the references based on the order in which they are presented. Submission of this statement should not be taken as an indication that a search has been conducted, or that no better art exists.

It is respectfully requested that the cited information be expressly considered during the prosecution of this application and the references made of record therein.

FEES

37 CFR 1.97(b): No fee is believed due in connection with this submission, because the information disclosure statement submitted herewith is satisfied by one of the following conditions ("X" indicates satisfaction): Within three months of the filing date of a national application other than a continued prosecution application under 37 CFR 1.53(d), or Within three months of the date of entry into the national stage of an international application as set forth in 37 CFR 1.491 or Before the mailing date of a first Office Action on the merits, or Before the mailing of a first Office action after the filing of a request for continued examination under 37 CFR 1.114. Although no fee is believed due, if any fee is deemed due in connection with this submission, please charge such fee to Deposit Account 19-1970.	
37 CFR 1.97(c): The information disclosure statement transmitted herewith is being filed after all the above conditions (37 CFR 1.97(b)), but before the mailing date of one of the following conditions: (1) a final action under 37 C.F.R. 1.113 or (2) a notice of allowance under 37 C.F.R. 1.311, or (3) an action that otherwise closes prosecution in the application. This Information Disclosure Statement is accompanied by: A Certification (below) as specified by 37 C.F.R. 1.97(e). Although no fee is believed due, if any fee is deemed due in connection with this submission, please charge such fee to Deposit Account 19-1970. OR Please charge Deposit Account 19-1970 in the amount of \$180.00 for the fee set forth in 37 C.F.R. 1.17(p) for submission of an information disclosure statement. Please credit any overpayment or charge any underpayment to Deposit Account 19-1970.	
37 CFR 1.97(d): This Information Disclosure Statement is being submitted after the period specified in 37 CFR 1.97(c). This information Disclosure Statement includes a Certification (below) as specified by 37 C.F.R. 1.97(e) AND Applicants hereby requests consideration of the reference(s) disclosed herein. Please charge Deposit Account 19-1970 in the amount of \$180.00 under 37 C.F.R. 1.17(p). Please credit any overpayment or charge any underpayment to Deposit Account 19-1970. Election to pay the fee should not be taken as an indication that applicant(s) cannot execute a certification.	

1	on (37 C.F.R. 1.97(e)) ble only if checked)
first cited in any communicat application not more than thr 1.97(e)(1).	a contained in this information disclosure statement was tion from a foreign patent office in a counterpart foreign ree months prior to the filing of this statement. 37 C.F.R. mmunication from the foreign patent office is enclosed.
	OR
No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in 37 C.F.R. 1.56(c) more than three months prior to the filing of this statement. 37 C.F.R. 1.97(e)(2).	
	Respectfully submitted,
	SHERIDAN ROSS P.C.
Date: February 3, 2011	By: Maela M. Domitrovich, Ph.D. Registration No. 62948 1560 Broadway, Suite 1200 Denver, Colorado 80202-5141 (303) 863-9700

Date: February 3, 2011